查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1463099

胃轻瘫药物市场、占有率、规模、趋势、行业分析报告：依药物类别、依疾病类别、依最终用户、依地区、依细分市场、预测，2024-2032 年

Gastroparesis Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections); By Disease Class; By End User; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，预计到2032年全球胃轻瘫药物市场规模将达到66.6235亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

由于需求增加和市场扩张的多种因素，全球胃轻瘫药物市场正在稳步成长。 胃轻瘫的特征是胃排空延迟，给受影响的人带来了重大课题，导致噁心、呕吐、腹胀和腹部不适等症状。 随着医疗保健专业人员和患者对这种疾病的认识不断提高，对有效治疗的需求持续增长，并推动胃轻瘫药物市场向前发展。

胃轻瘫药物市场成长的主要驱动力之一是胃肠道疾病（包括胃轻瘫）的盛行率不断增加。 由于饮食习惯、久坐生活方式的改变和糖尿病盛行率的增加，胃轻瘫的盛行率在全球范围内呈上升趋势。 患者数量的迅速增加为製药公司开发和商业化新药创造了巨大的市场机会，以满足这些患者未满足的医疗需求。 此外，人口老化，特别是在已开发地区，也导致患者数量增加，进一步推动市场成长。

此外，医疗技术和药物开发的进步正在促使胃轻瘫创新疗法的引入。 製药公司大力投资研发活动，以发现和开发具有更高功效和安全性的新药。 这些努力的结果是，出现了新型治疗剂，包括促胃动力剂、止吐剂和针对涉及胃动力障碍的特定途径的药物。 多样化的治疗选择为医疗保健提供者提供了更多选择，可以根据患者的个人需求量身定制治疗，从而推动市场成长。

胃轻瘫治疗药物市场报告重点

促动力药物细分市场在 2023 年占了显着占有率，因为它能够促进胃部肌肉的收缩和运动。

2023年，糖尿病性胃轻瘫细分市场所占占有率最大，这是由于人们生活方式和消费模式的变化导致糖尿病的显着盛行率。

由于零售药房连锁店的大幅扩张和患者获取便利，预计药房行业在预测期内将以最快的速度增长。

由于糖尿病盛行率上升和先进的医疗基础设施的存在，北美将在 2023 年主导全球市场

主要市场参与者包括 Medtronic Plc、Rhythm Pharmaceuticals、Vanda Pharmaceuticals、Abbott Laboratories、AbbVie Inc. 和 Pfizer Inc.。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第四章全球胃轻瘫药物市场洞察

  • 胃轻瘫药物市场 - 最终用户快照
  • 胃轻瘫药物市场动态
    • 推动者和机会
      • 糖尿病和老年人口的增加推动市场成长
      • 监管部门批准用于治疗胃轻瘫的新药将推动市场成长。
    • 抑制因素和课题
      • 缺乏新的治疗方案和限製成长的监管障碍
  • PESTEL 分析
  • 胃轻瘫治疗药物市场最终使用者趋势
  • 价值链分析
  • 新冠肺炎 (COVID-19) 影响分析

第 5 章依疾病类别划分的全球市场

  • 主要发现
  • 简介
  • 糖尿病胃轻瘫
  • 特发性胃轻瘫
  • 术后胃轻瘫
  • 其他

第 6 章依药物类别划分的世界市场

  • 主要发现
  • 简介
  • 胃肠动力促进剂
  • 止吐药
  • 肉毒桿菌注射

第 7 章最终用户的全球市场

  • 主要发现
  • 简介
  • 医院
  • 药房
  • 诊所
  • 电子商务

第 8 章依地区划分的世界市场

  • 主要发现
  • 简介
    • 胃轻瘫治疗药物市场评估，地区，2019-2032
  • 胃轻瘫药物市场 - 北美
    • 北美：2019-2032 年胃轻瘫药物市场（依疾病分类）
    • 北美：胃轻瘫药物市场，依最终用户划分，2019-2032 年
    • 北美：2019-2032 年胃轻瘫药物市场（依药物分类）
    • 胃轻瘫药物市场 - 美国
    • 胃轻瘫药物市场 - 加拿大
  • 胃轻瘫药物市场 - 欧洲
    • 欧洲：胃轻瘫药物市场，依疾病类别，2019-2032 年
    • 欧洲：胃轻瘫药物市场，依最终使用者划分，2019-2032 年
    • 欧洲：胃轻瘫药物市场，依药物类别，2019-2032 年
    • 胃轻瘫药物市场 - 英国
    • 胃轻瘫药物市场 - 法国
    • 胃轻瘫药物市场 - 德国
    • 胃轻瘫药物市场 - 义大利
    • 胃轻瘫药物市场 - 西班牙
    • 胃轻瘫药物市场 - 荷兰
    • 胃轻瘫药物市场 - 俄罗斯
  • 胃轻瘫药物市场 - 亚太地区
    • 亚太地区：胃轻瘫药物市场，依疾病类别，2019-2032 年
    • 亚太地区：胃轻瘫药物市场，依最终使用者划分，2019-2032 年
    • 亚太地区：胃轻瘫药物市场，依药物类别，2019-2032 年
    • 胃轻瘫治疗药物市场 - 中国
    • 胃轻瘫药物市场 - 印度
    • 胃轻瘫药物市场 - 马来西亚
    • 胃轻瘫治疗药物市场 - 日本
    • 胃轻瘫治疗药物市场 - 印度尼西亚
    • 胃轻瘫治疗药物市场 - 韩国
  • 胃轻瘫药物市场 - 中东和非洲
    • 中东和非洲：2019-2032 年胃轻瘫药物市场（依疾病类别）
    • 中东和非洲：胃轻瘫药物市场，依最终用户划分，2019-2032 年
    • 中东和非洲：2019-2032 年胃轻瘫药物市场（依药物类别）
    • 胃轻瘫药物市场 - 沙乌地阿拉伯
    • 胃轻瘫治疗药物市场 - 阿联酋
    • 胃轻瘫药物市场 - 以色列
    • 胃轻瘫药物市场 - 南非
  • 胃轻瘫药物市场 - 拉丁美洲
    • 拉丁美洲：胃轻瘫药物市场，依疾病类别，2019-2032 年
    • 拉丁美洲：胃轻瘫药物市场，依最终用户划分，2019-2032 年
    • 拉丁美洲：2019-2032 年胃轻瘫药物市场（依药物类别）
    • 胃轻瘫药物市场 - 墨西哥
    • 胃轻瘫药物市场 - 巴西
    • 胃轻瘫药物市场 - 阿根廷

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 合作/协作/合约/出版物

第十章公司简介

  • Abbott Laboratories（US）
  • AbbVie Inc.（US）
  • Allergan Inc.（US）
  • Evoke Pharma（US）
  • Medtronic Plc（Ireland）
  • Neurogastrx Inc.（US）
  • Pfizer Inc.（US）
  • Rhythm Pharmaceuticals Inc.（US）
  • Salix Pharmaceuticals（US）
  • TEVA Pharmaceutical（Israel）
  • Vanda Pharmaceuticals Inc.（US）
Product Code: PM4776

The global gastroparesis drugs market size is expected to reach USD 6,662.35 Million by 2032, according to a new study by Polaris Market Research. The report "Gastroparesis Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections); By Disease Class; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The gastroparesis drugs market has been experiencing steady growth globally, driven by several factors contributing to increased demand and market expansion. Gastroparesis, a condition characterized by delayed emptying of the stomach, poses significant challenges for affected individuals, leading to symptoms such as nausea, vomiting, bloating, and abdominal discomfort. As awareness about this condition grows among healthcare professionals and patients alike, the demand for effective treatments continues to rise, propelling the gastroparesis drugs market forward.

One of the primary driving factors behind the growth of the gastroparesis drugs market is the increasing prevalence of gastrointestinal disorders, including gastroparesis. With changing dietary habits, sedentary lifestyles, and rising incidences of diabetes, the incidence of gastroparesis is on the rise globally. This surge in patient numbers has created a substantial market opportunity for pharmaceutical companies to develop and commercialize novel drugs catering to the unmet medical needs of these individuals. Moreover, the aging population, particularly in developed regions, contributes to the growing patient pool, further boosting market growth.

Furthermore, advancements in medical technology and drug development have led to the introduction of innovative treatment options for gastroparesis. Pharmaceutical companies are investing significantly in research and development activities to discover and develop new drugs with improved efficacy and safety profiles. These efforts have resulted in the emergence of novel therapeutic agents, including prokinetic agents, antiemetics, and other drugs targeting specific pathways involved in gastric motility disorders. The availability of a diverse range of treatment options provides healthcare providers with more choices to tailor therapy according to individual patient needs, thereby driving market growth.

Gastroparesis Drugs Market Report Highlights

Prokinetic agents segment accounted for noteworthy share in 2023, that is due to its ability to boost stomach muscles contractions and movement

Diabetic gastroparesis segment held the maximum share in 2023, owing to significant prevalence of diabetes due to change in people lifestyle and consumption patterns

Pharmacies segment will grow at highest pace during forecast period, that is attributed to significant expansion of retail pharmacy chains and easy accessibility to patients

North America dominated the global market in 2023, on account of rising prevalence of diabetes and presence of advanced healthcare infrastructure

The key market players include Medtronic Plc, Rhythm Pharmaceuticals, Vanda Pharmaceuticals, Abbott Laboratories, AbbVie Inc., and Pfizer Inc.

Polaris Market Research has segmented the gastroparesis drugs market report based on drug class, disease class, end user, and region:

Gastroparesis Drugs, Drug Class Outlook (Revenue - USD Million, 2023 - 2032)

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Gastroparesis Drugs, Disease Class Outlook (Revenue - USD Million, 2023 - 2032)

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

Gastroparesis Drugs, End User Outlook (Revenue - USD Million, 2023 - 2032)

  • Hospitals
  • Pharmacies
  • Clinics
  • E-commerce

Gastroparesis Drugs, Regional Outlook (Revenue - USD Million, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Gastroparesis Drugs Market Insights

  • 4.1. Gastroparesis Drugs Market - End User Snapshot
  • 4.2. Gastroparesis Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of diabetes and geriatric population to boost market growth
      • 4.2.1.2. Regulatory approvals for new drugs for gastroparesis treatment to boost market growth.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of novel treatment options and regulatory hurdles to restrain growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Gastroparesis Drugs Market End User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Gastroparesis Drugs Market, by Disease Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • 5.3. Diabetic Gastroparesis
    • 5.3.1. Global Gastroparesis Drugs Market, by Diabetic Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.4. Idiopathic Gastroparesis
    • 5.4.1. Global Gastroparesis Drugs Market, by Idiopathic Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.5. Post-surgical Gastroparesis
    • 5.5.1. Global Gastroparesis Drugs Market, by Post-surgical Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.6. Others
    • 5.6.1. Global Gastroparesis Drugs Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Gastroparesis Drugs Market, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 6.3. Prokinetic Agents
    • 6.3.1. Global Gastroparesis Drugs Market, by Prokinetic Agents, by Region, 2019-2032 (USD Million)
  • 6.4. Antiemetic Agents
    • 6.4.1. Global Gastroparesis Drugs Market, by Antiemetic Agents, by Region, 2019-2032 (USD Million)
  • 6.5. Botulinum Toxin Injections
    • 6.5.1. Global Gastroparesis Drugs Market, by Botulinum Toxin Injections, by Region, 2019-2032 (USD Million)

7. Global Gastroparesis Drugs Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Global Gastroparesis Drugs Market, by Hospitals, By Region, 2019-2032 (USD Million)
  • 7.4. Pharmacies
    • 7.4.1. Global Gastroparesis Drugs Market, by Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Clinics
    • 7.5.1. Global Gastroparesis Drugs Market, by Clinics, By Region, 2019-2032 (USD Million)
  • 7.6. E-commerce
    • 7.6.1. Global Gastroparesis Drugs Market, by E-commerce, By Region, 2019-2032 (USD Million)

8. Global Gastroparesis Drugs Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Gastroparesis Drugs Market - North America
    • 8.3.1. North America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.3.2. North America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.3.3. North America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.3.4. Gastroparesis Drugs Market - U.S.
      • 8.3.4.1. U.S.: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.3.5. Gastroparesis Drugs Market - Canada
      • 8.3.5.1. Canada: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.4. Gastroparesis Drugs Market - Europe
    • 8.4.1. Europe: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.4.3. Europe: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.4. Gastroparesis Drugs Market - UK
      • 8.4.4.1. UK: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.5. Gastroparesis Drugs Market - France
      • 8.4.5.1. France: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.5.3. France: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.6. Gastroparesis Drugs Market - Germany
      • 8.4.6.1. Germany: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.7. Gastroparesis Drugs Market - Italy
      • 8.4.7.1. Italy: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.8. Gastroparesis Drugs Market - Spain
      • 8.4.8.1. Spain: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.9. Gastroparesis Drugs Market - Netherlands
      • 8.4.9.1. Netherlands: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.10. Gastroparesis Drugs Market - Russia
      • 8.4.10.1. Russia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.5. Gastroparesis Drugs Market - Asia Pacific
    • 8.5.1. Asia Pacific: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.4. Gastroparesis Drugs Market - China
      • 8.5.4.1. China: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.4.3. China: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.5. Gastroparesis Drugs Market - India
      • 8.5.5.1. India: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.5.3. India: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.6. Gastroparesis Drugs Market - Malaysia
      • 8.5.6.1. Malaysia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.7. Gastroparesis Drugs Market - Japan
      • 8.5.7.1. Japan: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.8. Gastroparesis Drugs Market - Indonesia
      • 8.5.8.1. Indonesia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.9. Gastroparesis Drugs Market - South Korea
      • 8.5.9.1. South Korea: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.6. Gastroparesis Drugs Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.4. Gastroparesis Drugs Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.5. Gastroparesis Drugs Market - UAE
      • 8.6.5.1. UAE: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.6. Gastroparesis Drugs Market - Israel
      • 8.6.6.1. Israel: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.7. Gastroparesis Drugs Market - South Africa
      • 8.6.7.1. South Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.7. Gastroparesis Drugs Market - Latin America
    • 8.7.1. Latin America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.4. Gastroparesis Drugs Market - Mexico
      • 8.7.4.1. Mexico: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.5. Gastroparesis Drugs Market - Brazil
      • 8.7.5.1. Brazil: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.6. Gastroparesis Drugs Market - Argentina
      • 8.7.6.1. Argentina: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories (US)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AbbVie Inc. (US)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Allergan Inc. (US)
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Evoke Pharma (US)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Medtronic Plc (Ireland)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Neurogastrx Inc. (US)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Pfizer Inc. (US)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Rhythm Pharmaceuticals Inc. (US)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Salix Pharmaceuticals (US)
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. TEVA Pharmaceutical (Israel)
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Vanda Pharmaceuticals Inc. (US)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development

List of Tables

  • Table 1 Global Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 2 Global Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 3 Global Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 4 Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 6 North America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 7 North America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 8 U.S.: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 9 U.S.: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 10 U.S.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 11 Canada: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 12 Canada: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 13 Canada: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 14 Europe: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 15 Europe: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 16 Europe: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 17 UK: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 18 UK: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 19 UK: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 20 France: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 21 France: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 22 France: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 23 Germany: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 24 Germany: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 25 Germany: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 26 Italy: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 27 Italy: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 28 Italy: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 29 Spain: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 30 Spain: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 31 Spain: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 32 Netherlands: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 33 Netherlands: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 34 Netherlands: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 35 Russia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 36 Russia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 37 Russia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 41 China: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 42 China: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 43 China: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 44 India: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 45 India: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 46 India: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 47 Malaysia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 48 Malaysia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 49 Malaysia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 50 Japan: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 51 Japan: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 52 Japan: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 53 Indonesia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 54 Indonesia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 55 Indonesia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 56 South Korea: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 57 South Korea: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 58 South Korea: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 65 UAE: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 66 UAE: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 67 UAE: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 68 Israel: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 69 Israel: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 70 Israel: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 71 South Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 72 South Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 73 South Africa: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 74 Latin America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 75 Latin America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 76 Latin America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 77 Mexico: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 78 Mexico: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 79 Mexico: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 80 Brazil: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 81 Brazil: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 82 Brazil: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 83 Argentina: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 84 Argentina: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 85 Argentina: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Gastroparesis Drugs Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Gastroparesis Drugs Market, by Drug Class, 2022 & 2032 (USD Million)
  • Figure 8. Market by Disease Class
  • Figure 9. Global Gastroparesis Drugs Market, by Disease Class, 2022 & 2032 (USD Million)
  • Figure 10. Market by End User
  • Figure 11. Global Gastroparesis Drugs Market, by End User, 2022 & 2032 (USD Million)
  • Figure 12. Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Gastroparesis Drugs Market